Fenoldopam: Difference between revisions
ClaireLewis (talk | contribs) |
|||
| (12 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antihypertensive, Dopamine agonist | *Type: [[Antihypertensive]], Dopamine agonist | ||
*Dosage Forms: | *Dosage Forms: 10mg/mL (1 mL), 20mg/2 mL (2 mL) | ||
*Routes of Administration: Intravenous | *Routes of Administration: Intravenous | ||
*Common Trade Names: Corlopam | *Common Trade Names: Corlopam | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Severe hypertension: Initial 0.01 to 0.3 | *Severe hypertension: Initial 0.01 to 0.3 mcg/kg/minute, increase incrementally 0.05 to 0.1 mcg/kg/minute q 15 minute until target blood pressure is reached (maximum dose recorded in the study was 1.6 mcg/kg/minute), limit for up to 48-hour use. | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 12: | Line 12: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Not defined | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Not defined | ||
*Pediatric: | *Pediatric: Not defined | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: Not defined | ||
*Pediatric: | *Pediatric: Not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Caution if: | |||
**sulfite hypersensitivity | |||
**asthma | |||
**glaucoma, intraocular HTN, elevated ICP | |||
**acute stroke | |||
**cardiac disease, arrythmias | |||
**hypokalemia | |||
**active bleeding | |||
**portal hypertension | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*hypotension, severe | |||
*tachycardia | |||
*CHF, MI, angina | |||
*hypokalemia | |||
*leukocytosis | |||
===Common=== | ===Common=== | ||
*headache, dizziness | |||
*flushing, diaphoresis, anxiety, tachycardia | |||
*hypotension | |||
*ST-T wave changes | |||
*nausea/vomiting, abdominal pain, diarrhea, constipation | |||
*injection site reaction | |||
*back pain | |||
*nasal congestion | |||
*IOP elevation | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 5 min | ||
*Metabolism: | *Metabolism: Liver extensively; CYP450 | ||
*Excretion: | *Excretion: urine 90%, feces 10% | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*stimulates dopamine D1-like and α-2 adrenergic receptors | |||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[Hypertension]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] | |||
Latest revision as of 19:47, 22 September 2019
Administration
- Type: Antihypertensive, Dopamine agonist
- Dosage Forms: 10mg/mL (1 mL), 20mg/2 mL (2 mL)
- Routes of Administration: Intravenous
- Common Trade Names: Corlopam
Adult Dosing
- Severe hypertension: Initial 0.01 to 0.3 mcg/kg/minute, increase incrementally 0.05 to 0.1 mcg/kg/minute q 15 minute until target blood pressure is reached (maximum dose recorded in the study was 1.6 mcg/kg/minute), limit for up to 48-hour use.
Pediatric Dosing
- Severe hypertension: Initial 0.2 mcg/kg/minute; increase incrementally 0.3 to 0.5 mcg/kg/minute q 20 to 30 minutes (maximum 0.8 mcg/kg/minute), limit for 4-hour use
Special Populations
- Pregnancy Rating: B
- Lactation risk: Not defined
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Caution if:
- sulfite hypersensitivity
- asthma
- glaucoma, intraocular HTN, elevated ICP
- acute stroke
- cardiac disease, arrythmias
- hypokalemia
- active bleeding
- portal hypertension
Adverse Reactions
Serious
- hypotension, severe
- tachycardia
- CHF, MI, angina
- hypokalemia
- leukocytosis
Common
- headache, dizziness
- flushing, diaphoresis, anxiety, tachycardia
- hypotension
- ST-T wave changes
- nausea/vomiting, abdominal pain, diarrhea, constipation
- injection site reaction
- back pain
- nasal congestion
- IOP elevation
Pharmacology
- Half-life: 5 min
- Metabolism: Liver extensively; CYP450
- Excretion: urine 90%, feces 10%
Mechanism of Action
- stimulates dopamine D1-like and α-2 adrenergic receptors